<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04773093</url>
  </required_header>
  <id_info>
    <org_study_id>IndonesiaUAnes057</org_study_id>
    <nct_id>NCT04773093</nct_id>
  </id_info>
  <brief_title>Effect of Continous Intravenous Lidocaine Infusion Intraoperative for Craniotomy Tumor Removal Surgery</brief_title>
  <official_title>Continous Intravenous Lidocaine Infusion Intraoperative for Craniotomy Tumor Removal Surgery: Effect to Brain Relaxation, Opioid Consumption and Postoperative Cognitive Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to compare continous intravenous lidocaine infusion and placebo on the&#xD;
      effect to brain relaxation, opioid consumption and postoperative cognitive status in adult&#xD;
      patient undergoing craniotomy tumor removal surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifty subjects were given informed consent one day before surgery and then randomized into&#xD;
      two groups: continous intravenous Lidocaine intraoperative and Placebo. Patient, the&#xD;
      Anesthesist as data collector, and the Neurosurgeon as the outcome assessor are blinded to&#xD;
      the randomization and the intervention given. Non invasive blood pressure, ECG, and pulse&#xD;
      oxymetry monitor were set on the subject in the operating room. General anesthesia induction&#xD;
      was done by Fentanyl 3 mcg/kg, Lidocaine 1.5 mg/kg or Placebo (according to allocation&#xD;
      group), Propofol 1-2 mg/kg and Rocuronium 1 mg/kg. After the intubation, maintenance&#xD;
      continous intravenous Lidocain dose 2 mg/kg/hours or Placebo were set until the completion of&#xD;
      surgery. Other than intervention (Lidocain or Placebo), maintenance was done by volatile&#xD;
      Sevoflurane 0.8 -1.0 MAC, intermittent Fentanyl, continous Atracurium dose 5 mcg/kg/minutes&#xD;
      and Manitol 20% dose 0.5 g/kg 30 minutes before Neurosurgeon reach the duramater. At the time&#xD;
      Neurosurgeon reach the duramater, before and after they open the duramater, Neurosurgeon will&#xD;
      assess brain relaxation by direct inspection and palpation. Total Fentanyl intraoperative&#xD;
      will record and Cognitive status pre and postoperative will assess using MMSE.&#xD;
      Postoperatively patient will transport to the ICU for monitoring.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain relaxation</measure>
    <time_frame>Up to 1 minute after duramater opening</time_frame>
    <description>Measure by direct inspection and palpation of duramater and brain by Neurosurgeon. The result is using four points scale, grading the brain as completely relaxed, satisfactorily relaxed, firm and bulging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preoperative cognitive status</measure>
    <time_frame>During preanesthesia assessment</time_frame>
    <description>Measured by using MMSE questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative cognitive status</measure>
    <time_frame>24-hours after surgery</time_frame>
    <description>Measured by using MMSE questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative cognitive status</measure>
    <time_frame>36-hours after surgery</time_frame>
    <description>Measured by using MMSE questionnaire</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Craniotomy Tumor Removal Surgery</condition>
  <arm_group>
    <arm_group_label>Continous Intravenous Lidocaine Infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will recieve Continous Intravenous Lidocaine Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient will recieve placebo (NaCl 0.9% infusion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continous Intravenous Lidocaine Infusion</intervention_name>
    <description>Patient will recieve intravenous Lidocaine dose 1.5 mg/kg at the time of induction and after that will receive maintenance by continous intravenous Lidocaine infusion dose 2 mg/kg/hour until the completion of surgery</description>
    <arm_group_label>Continous Intravenous Lidocaine Infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patient will recieve Placebo NaCl 0.9% continuous intravenous infusion until the completion of surgery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient age 18-65 years old undergo craniotomy tumor removal surgery&#xD;
&#xD;
          -  Physical status ASA 1-3&#xD;
&#xD;
          -  Compos mentis (GCS 15)&#xD;
&#xD;
          -  Operation using pin head fixation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient or family refused to participate&#xD;
&#xD;
          -  Has Atrioventricular block rhytm on ECG&#xD;
&#xD;
          -  Has sign of circulation shock&#xD;
&#xD;
          -  Midline shift &gt; 5.4 mm on brain imaging&#xD;
&#xD;
          -  Diagnose with Glioblastoma multiforme or Metastatic&#xD;
&#xD;
          -  Vascular surgery&#xD;
&#xD;
          -  Using CSF drainage (EVD, VP shunt, or Lumbal drain)&#xD;
&#xD;
          -  Routine using or in treatmet using adrenergic agonist or antagonist drugs&#xD;
&#xD;
          -  Routine consumption of opioid in last two weeks before surgery&#xD;
&#xD;
          -  History of Local anesthetic hypersensitivity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aida Tantri</last_name>
    <phone>+628161832487</phone>
    <email>aidatantri@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National General Hospital Dr. Cipto Mangunkusumo</name>
      <address>
        <city>Jakarta Pusat</city>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aida Tantri, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <results_reference>
    <citation>de Robles P, Fiest KM, Frolkis AD, Pringsheim T, Atta C, St Germaine-Smith C, Day L, Lam D, Jette N. The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro Oncol. 2015 Jun;17(6):776-83. doi: 10.1093/neuonc/nou283. Epub 2014 Oct 13. Review.</citation>
    <PMID>25313193</PMID>
  </results_reference>
  <results_reference>
    <citation>Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G. Epidemiology of metastatic brain tumors. Neurosurg Clin N Am. 2011 Jan;22(1):1-6, v. doi: 10.1016/j.nec.2010.08.007. Review.</citation>
    <PMID>21109143</PMID>
  </results_reference>
  <results_reference>
    <citation>Dunn LK, Durieux ME. Perioperative Use of Intravenous Lidocaine. Anesthesiology. 2017 Apr;126(4):729-737. doi: 10.1097/ALN.0000000000001527. Review.</citation>
    <PMID>28114177</PMID>
  </results_reference>
  <results_reference>
    <citation>Weibel S, Jelting Y, Pace NL, Helf A, Eberhart LH, Hahnenkamp K, Hollmann MW, Poepping DM, Schnabel A, Kranke P. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults. Cochrane Database Syst Rev. 2018 Jun 4;6:CD009642. doi: 10.1002/14651858.CD009642.pub3. Review.</citation>
    <PMID>29864216</PMID>
  </results_reference>
  <results_reference>
    <citation>Dunbar PJ, Visco E, Lam AM. Craniotomy procedures are associated with less analgesic requirements than other surgical procedures. Anesth Analg. 1999 Feb;88(2):335-40.</citation>
    <PMID>9972752</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 20, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Susilo Chandra</investigator_full_name>
    <investigator_title>MD, FRCA</investigator_title>
  </responsible_party>
  <keyword>intravenous lidocaine</keyword>
  <keyword>craniotomy</keyword>
  <keyword>brain relaxation</keyword>
  <keyword>opioid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

